Mira Robotics, Inc. is a Japanese company based in Kawasaki City that specializes in designing and developing a Robot as a Service (RaaS) platform. Established in 2018, the company focuses on providing comprehensive services in robot development, robot intelligence, and cloud collaboration. Mira Robotics aims to integrate software solutions to enhance robotic capabilities across various fields, facilitating advancements in automation and intelligent systems.
Melody International Japan is a company that supports medical and health with ICT.
Metcela Inc. specializes in developing fibroblast-based therapies for cardiac diseases, focusing on regenerative medicine for conditions such as Ischemic Heart Disease. Founded in 2016 and based in Kawasaki-shi, Japan, the company utilizes VCAM-1-positive cardiac fibroblasts derived from patients' own cells. This innovative approach aims to replenish and restore damaged cardiac muscle and its surrounding microenvironment, enhancing the heart's natural healing capabilities. By repairing rather than replacing damaged cells, Metcela seeks to provide effective and cost-efficient treatments for heart failure, offering new hope for patients suffering from cardiac ailments.
AdipoSeeds, though a novel technology, creates platelets from mesenchymal stem cells without a complex and costly gene transfer. It aims to invent new blood supply system to solve the shortage of platelets in the world, and to create a future where a platelet-related treatment will be cheaply and safely provided.
Luxonus is engaged in the development of advanced imaging devices utilizing photoacoustic technology. This innovative approach allows for the early detection and diagnosis of diseases by producing ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. The device operates safely and effectively without exposing patients to harmful radiation, as it combines optical and ultrasonic waves. By providing detailed insights into the onset of diseases, the healing process, and health conditions before and after illness, Luxonus aims to enhance the diagnostic capabilities available to healthcare professionals.
Integral Geometry Science Inc., founded in 2012 and based in Kobe, Japan, specializes in the design and development of measurement devices and software for image data processing. The company focuses on the inverse analysis theory of electromagnetic and scattered fields, particularly through its innovative microwave mammography system. This technology effectively addresses the challenges associated with scattering microwaves in high-density breasts, producing clear images that assist healthcare professionals in accurately distinguishing between cancerous and normal tissue. By providing a more reliable imaging solution, Integral Geometry Science aims to reduce unnecessary pain and radiation exposure for patients compared to traditional screening methods. Additionally, the company manufactures a nondestructive inspection system specifically for lithium-ion batteries.
iXs is a start-up to solve social problems with robot technology.In addition to the development of inspection / business robots and special environment-compatible robots that we have been conducting so far, we have developed and operated AI / Data Service systems and analyzed big data. We provide products and services. We provide consistent support from introduction to operation of products and services that can be used and used, to solve customer issues.
Integral Geometry Science Inc., founded in 2012 and based in Kobe, Japan, specializes in the design and development of measurement devices and software for image data processing. The company focuses on the inverse analysis theory of electromagnetic and scattered fields, particularly through its innovative microwave mammography system. This technology effectively addresses the challenges associated with scattering microwaves in high-density breasts, producing clear images that assist healthcare professionals in accurately distinguishing between cancerous and normal tissue. By providing a more reliable imaging solution, Integral Geometry Science aims to reduce unnecessary pain and radiation exposure for patients compared to traditional screening methods. Additionally, the company manufactures a nondestructive inspection system specifically for lithium-ion batteries.
StemRIM is a biotechnology company based in Ibaraki, Japan, founded in 2006. The company specializes in the development of regeneration-guided medicines aimed at treating challenging diseases such as epidermolysis bullosa, cerebral infarction, and myocardial infarction. StemRIM's innovative approach involves mobilizing the body's own stem cells to target injured or diseased tissues without the need for extraction. Their product portfolio includes PJ1 regeneration induction medicine using HMGB1 peptides, PJ2 and PJ3 regeneration-inducing drugs and proteins, as well as the PJ4 therapeutic autologous cell collection device and PJ5 stem cell gene therapy technology. Through its research and development efforts, StemRIM seeks to advance the field of regenerative medicine and provide effective treatment options for patients with intractable conditions.
Miraikikai, Inc. is a Japanese company founded in 2004, based in Takamatsu, Japan. It specializes in the development, manufacturing, distribution, and maintenance of robotics and mechatronics products. The company produces solar cleaning robots and offers a 3D Laser Sensor, designed for non-contact measurement across various applications such as pipes, tanks, and structural components. Originating from Kagawa University, Miraikikai focuses on creating intelligent mobile robots for professional use, leveraging advanced mechanical design and control technology informed by extensive field research. Additionally, the company provides technical consultation and development solutions to enhance its offerings.
Metcela Inc. specializes in developing fibroblast-based therapies for cardiac diseases, focusing on regenerative medicine for conditions such as Ischemic Heart Disease. Founded in 2016 and based in Kawasaki-shi, Japan, the company utilizes VCAM-1-positive cardiac fibroblasts derived from patients' own cells. This innovative approach aims to replenish and restore damaged cardiac muscle and its surrounding microenvironment, enhancing the heart's natural healing capabilities. By repairing rather than replacing damaged cells, Metcela seeks to provide effective and cost-efficient treatments for heart failure, offering new hope for patients suffering from cardiac ailments.
Renascience is a pharmaceuticals company focused on the research and development of innovative medical solutions. It employs a range of modalities, including pharmaceuticals, medical devices, and artificial intelligence, to address challenges within the healthcare sector. By integrating these diverse approaches, Renascience aims to create effective interventions that enhance patient care and improve health outcomes.
CODE Meee Inc. engages in the production of scents. CODE Meee Inc. was founded in 2017 and is based in Yokohama, Japan.
Cyfuse Biomedical develops tissue fabrication systems and cell-based products in Japan and internationally. The company offers 3D BioFabrication systems and related consumables; develops and licenses 3D tissue products for therapeutic and drug development use; and engages in contract manufacturing of 3D tissue products for research purposes.
Its products applications include blood vessel grafts for blood access of hemodialysis patients or coronary artery bypass grafts; cardiac grafts for drug toxicology screening or supplemental therapy of myocardial infarction; cartilage grafts for plastic surgery or reconstruction; and hepatocyte grafts for drug metabolism screening or in-vivo production of clotting factors in the treatment of hemophilia.
Cyfuse Biomedical was founded in 2010 and is based in Tokyo, Japan.
StemRIM is a biotechnology company based in Ibaraki, Japan, founded in 2006. The company specializes in the development of regeneration-guided medicines aimed at treating challenging diseases such as epidermolysis bullosa, cerebral infarction, and myocardial infarction. StemRIM's innovative approach involves mobilizing the body's own stem cells to target injured or diseased tissues without the need for extraction. Their product portfolio includes PJ1 regeneration induction medicine using HMGB1 peptides, PJ2 and PJ3 regeneration-inducing drugs and proteins, as well as the PJ4 therapeutic autologous cell collection device and PJ5 stem cell gene therapy technology. Through its research and development efforts, StemRIM seeks to advance the field of regenerative medicine and provide effective treatment options for patients with intractable conditions.
Rena Therapeutics Inc. is a pharmaceutical company based in Tsukuba, Japan, founded in January 2015. The company specializes in developing nucleic acid medicines designed for innovative drug delivery systems targeting various tumors, including glioma, melanoma, and several types of leukemia and lymphoma. Rena Therapeutics focuses on addressing unmet medical needs in cancer and other difficult-to-treat diseases by leveraging the advantages of nucleic acid drugs. These advantages include the ability to specifically target intracellular drug molecules, conduct drug discovery for any gene with the appropriate delivery technology, and offer a more precise treatment option with potentially fewer side effects. Additionally, the company's Hetero-Duplex oligonucleotides technology facilitates the design and development of nucleic acid therapeutics, allowing for a more efficient pipeline in drug discovery.
Spectronics is a development of new technologies and new applications to bring about innovation, focusing on the future of laser technology.
Z-Works Inc. is a technology company based in Tokyo, Japan, specializing in Internet of Things (IoT) solutions. Founded in 2015, the company offers a range of IoT devices, including various types of sensors, smart locks, and smart meters. In addition to its hardware, Z-Works provides consulting services to support proof of concept and develop sensor packages for specific applications. The company's flagship product, the Z-Works Life Engine, is a cloud-based IoT platform that enables users to collect and analyze data from devices equipped with Z-Wave technology. This platform allows for remote monitoring and control of connected devices through a smartphone interface.
Spectronics is a development of new technologies and new applications to bring about innovation, focusing on the future of laser technology.
Kringle Pharma, Inc. is a biopharmaceutical company focused on the research and development of hepatocyte growth factor (HGF) protein medicines and NK4 molecules. Established in 2001 and headquartered in Japan, the company aims to harness the regenerative properties of HGF for various medical conditions, including acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury, and vocal fold scarring. In addition to HGF, Kringle Pharma develops NK4, which acts as an antagonist to HGF and exhibits anti-cancer properties by inhibiting tumor cell invasion and metastasis. The company's product pipeline includes recombinant human HGF for treating acute renal failure, skin ulcers, and central nervous system disorders, as well as NK4 and NK4 gene therapies for cancer treatment.
Starsphere K.K. is a technology company based in Machida, Japan, founded in 2012, that focuses on providing innovative information technology solutions for the healthcare industry. The company specializes in the development and delivery of its cloud-based data gathering and real-time analysis tool, DOKODEMOFORM EDC, which integrates electronic data capture (EDC) and clinical trial management system (CTMS) functionalities. Starsphere aims to transform the processes of data collection, analysis, and utilization in life sciences, with the vision of enhancing the efficiency and safety of medical treatments. By leveraging advanced technologies, Starsphere seeks to support healthcare professionals in delivering better and faster treatment options to patients.
Stem Cell & Device Laboratory, Inc. focuses on research and development, manufacturing, and sales of cellular products, devices, and integrated cell-material products specifically designed for drug discovery applications. The company specializes in creating innovative scaffold materials that enhance cell functionality and compatibility, leveraging advanced micro-engineering and nanofabrication technologies. Founded in 2014 and headquartered in Kyoto, Japan, Stem Cell & Device Laboratory is dedicated to advancing cell applications that contribute to a healthier society.
Ipoca is a Tokyo-based company that specializes in creating digital solutions for the retail and distribution sectors. Established in 2007, it has developed an information marketing platform that enhances the shopping experience by allowing users to access and store information about specific stores. The platform leverages smartphone-based behavioral data, including location, online search results, and purchase history, to help retailers attract new customers and improve customer retention. By promoting the unique appeal of local businesses, Ipoca aims to contribute to the revitalization of both local and national economies in Japan.
Nanoegg is aiming to create a medical breakthrough from skin research and to realize medical care without the use of needles.
Fileforce is a Tokyo-based company founded in 2001 that specializes in providing secure and scalable cloud file services for businesses of all sizes. The company offers a platform that allows enterprises to safely store, manage, access, and share files from various devices, including computers, tablets, and smartphones. Fileforce focuses on protecting valuable information and assets through its security management system, which includes enterprise cloud monitoring to facilitate the management of business activities such as proposals, quotations, and design documents. By enabling efficient file organization and sharing, Fileforce aims to enhance productivity and streamline operations for its clients.
TMS Co., Ltd. is a Tokyo-based clinical-stage biotechnology company specializing in the development of drug candidates and medical technologies derived from academic research. Founded in 2005, TMS focuses on fungus-derived small molecule compounds known as SMTPs, which exhibit dual modes of action, providing both thrombolytic and anti-inflammatory effects. The company's lead compound, TMS-007, is currently undergoing Phase IIa clinical trials for the treatment of acute ischemic stroke and is partnered with a prominent biotech firm. TMS aims to advance its innovative medical products to address significant health challenges.
Rena Therapeutics Inc. is a pharmaceutical company based in Tsukuba, Japan, founded in January 2015. The company specializes in developing nucleic acid medicines designed for innovative drug delivery systems targeting various tumors, including glioma, melanoma, and several types of leukemia and lymphoma. Rena Therapeutics focuses on addressing unmet medical needs in cancer and other difficult-to-treat diseases by leveraging the advantages of nucleic acid drugs. These advantages include the ability to specifically target intracellular drug molecules, conduct drug discovery for any gene with the appropriate delivery technology, and offer a more precise treatment option with potentially fewer side effects. Additionally, the company's Hetero-Duplex oligonucleotides technology facilitates the design and development of nucleic acid therapeutics, allowing for a more efficient pipeline in drug discovery.
Megakaryon Corporation develops platelets and red blood cells from human iPS cell lines. Its portfolio includes blood products that do not depend on blood donations. The company was founded in 2011 and is based in Kyoto, Japan with an additional office in Tokyo, Japan.
BrightPath Biotherapeutics Co., Ltd. is a biopharmaceutical company based in Kurume, Japan, dedicated to developing innovative cancer immunotherapy treatments. The company focuses on peptide vaccine technology designed to enhance the immune response against tumor-associated antigens. Its lead candidate, ITK-1, is a cancer peptide vaccine currently undergoing Phase III clinical trials for prostate cancer. In addition, BrightPath is advancing GRN-1201, which is in Phase II clinical trials for non-small cell lung cancer and Phase I trials for melanoma. The company is also researching GRN-1301, aimed at treating drug-resistant non-small cell lung cancer, and iPS-NKT, a therapy utilizing induced pluripotent stem cell-derived regenerated NKT cells. Founded in 2003 and previously known as GreenPeptide Co., Ltd., BrightPath Biotherapeutics rebranded in July 2017 to reflect its focus on biotherapeutics.
REGiMMUNE Corporation is a biotechnology company based in Tokyo, Japan, with an office in San Francisco, California. Founded in 2006, it specializes in developing immune-regulatory therapeutics aimed at treating life-threatening diseases and disorders. The company utilizes its proprietary reVax technology, which induces regulatory T cells to promote immune tolerance against specific disease-causing antigens. REGiMMUNE's product pipeline includes RGI-2001, currently in a Phase I/II clinical trial for treating Graft versus Host Disease associated with hematopoietic stem cell transplantation, as well as RGI-3001, a preclinical candidate for type 1 diabetes. Its portfolio also addresses a range of conditions, including allergies, autoimmune diseases, and transplantation disorders, with a focus on reducing the side effects commonly associated with conventional immunosuppressants. The company's research efforts are directed towards developing innovative solutions for various immune system disorders, including rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus.
Ipoca is a Tokyo-based company that specializes in creating digital solutions for the retail and distribution sectors. Established in 2007, it has developed an information marketing platform that enhances the shopping experience by allowing users to access and store information about specific stores. The platform leverages smartphone-based behavioral data, including location, online search results, and purchase history, to help retailers attract new customers and improve customer retention. By promoting the unique appeal of local businesses, Ipoca aims to contribute to the revitalization of both local and national economies in Japan.
CONNECTEC JAPAN Corporation develops semiconductor and electrical products. The company develops and provides foundry service of semiconductor package. It also provides technical support services for SMT, as well as various evaluation, analysis, and reliability test services. The company was founded in 2009 and is based in Myoko, Japan. It has a satellite in Kyoto, Japan, as well as sales offices in Seoul, Korea; and Suzhou, China.